Deller M, Huth K
Innere Abteilung, Diakonissen-Krankenhaus, Frankfurt.
Fortschr Med. 1992 Sep 10;110(25):463-6.
The present paper is intended to provide an overview of the arguments for and against drug treatment of hyperlipidemia.
An argument in support of lipid-lowering prophylactic and therapeutic programs is the close relationship between lipid levels and coronary heart disease, which has been documented both epidemiologically and by interventional studies. Arguments against comprehensive treatment of hyperlipidemia have to do with the fact that although large interventional studies have shown a reduction in mortality from coronary heart disease, there has been no reduction in overall mortality. Of decisive importance for the decision to apply lipid-lowering treatment is the overall risk profile of the patient concerned. This includes not only pathological lipid levels, but also numerous other factors that must be taken into account when considering the indication.
Whether to initiate lipid-lowering treatment or not should be determined on the basis of the individual patient's risk profile, with additional consideration being given to age and sex.
本文旨在概述支持和反对高脂血症药物治疗的观点。
支持降脂预防和治疗方案的一个观点是血脂水平与冠心病之间的密切关系,这一点已在流行病学研究和干预性研究中得到证实。反对全面治疗高脂血症的观点与以下事实有关:尽管大型干预性研究表明冠心病死亡率有所降低,但总体死亡率并未降低。对于决定是否应用降脂治疗而言,相关患者的整体风险状况至关重要。这不仅包括病理性血脂水平,还包括在考虑适应症时必须考虑的许多其他因素。
是否启动降脂治疗应根据个体患者的风险状况来决定,同时还应额外考虑年龄和性别。